12,218 Shares in Harrow, Inc. (NASDAQ:HROW) Bought by Quantbot Technologies LP

Quantbot Technologies LP acquired a new stake in Harrow, Inc. (NASDAQ:HROW) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,218 shares of the company’s stock, valued at approximately $549,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its position in Harrow by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after acquiring an additional 21,253 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Harrow in the third quarter valued at approximately $1,267,000. Penserra Capital Management LLC purchased a new stake in shares of Harrow during the third quarter worth approximately $1,986,000. SG Americas Securities LLC acquired a new stake in shares of Harrow during the third quarter worth $534,000. Finally, Semanteon Capital Management LP purchased a new position in Harrow in the 3rd quarter valued at $686,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HROW. Craig Hallum upped their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. B. Riley reissued a “buy” rating and set a $50.00 price target on shares of Harrow in a report on Thursday, August 29th. Finally, Lake Street Capital lifted their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th.

Harrow Price Performance

Harrow stock opened at $41.86 on Tuesday. The company has a market cap of $1.49 billion, a P/E ratio of -44.53 and a beta of 0.76. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23. The business has a fifty day moving average of $47.56 and a two-hundred day moving average of $34.87. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.